Alpha-1 blockers and susceptibility to COVID-19 in benign prostate hyperplasia patients : an international cohort study
Authors/Creators
- Akihiko Nishimura
- Junqing Xie
- Kristin Kostka
- Talita Duarte-Salles
- Sergio Fernández Bertolín
- María Aragón
- Clair Blacketer
- Azza Shoaibi
- Scott L DuVall
- Kristine Lynch
- Michael E Matheny
- Thomas Falconer
- Daniel R Morales
- Mitchell M Conover
- Seng Chan You
- Nicole Pratt
- James Weaver
- Anthony G Sena
- Martijn J Schuemie
- Jenna Reps
- Christian Reich
- Peter R Rijnbeek
- Patrick B Ryan
- George Hripcsak
- Daniel Prieto-Alhambra
- Marc A Suchard
Description
Alpha-1 blockers, often used to treat benign prostate hyperplasia (BPH), have been hypothesized to prevent COVID-19 complications by minimising cytokine storms release. We conducted a prevalent-user active-comparator cohort study to assess association between alpha-1 blocker use and risks of three COVID-19 outcomes: diagnosis, hospitalization, and hospitalization requiring intensive services. Our study included 2.6 and 0.46 million users of alpha-1 blockers and of alternative BPH therapy during the period between November 2019 and January 2020, found in electronic health records from Spain (SIDIAP) and the United States (Department of Veterans Affairs, Columbia University Irving Medical Center, IQVIA OpenClaims, Optum DOD, Optum EHR). We estimated hazard ratios using state-of-the-art techniques to minimize potential confounding, including largescale propensity score matching/stratification and negative control calibration. We found no differential risk for any of COVID-19 outcome, pointing to the need for further research on potential COVID-19 therapies.
Files
2021 - Nishimura - Alpha-1 blockers and susceptibility to COVID-19 in benign prostate hyperplasia patients an international cohort study.pdf
Files
(2.2 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:3395f933a9c3f112870877cb0feb73e3
|
2.2 MB | Preview Download |